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The number of members in the family Herpesviridae has increased in the last 10 years due to the description of three 
novel human herpesviruses: human herpesvirus 6 (HHV-6) in 1986, human herpesvirus 7 (HHV-7) in 1990, and human 
herpesvirus 8 (HHV-8), also known as Kaposi‘s sarcoma-associated herpesvirus (KSHV), in 1994. HHV-6 and HHV-7 were 
first isolated from blood lymphocyte cultures, while HHV-8 was identified following a specific molecular biology 
approach in the search for the etiologic agent of Kaposi’s sarcoma. The three viruses are lymphotropic, T-cells being the 
targets of HHV-6 and HHV-7, and B-cells being probably those of HHV-8. The ability to be propagated in cell cultures in 
vitro differs according to the virus concerned: this can be done readily with HHV-6, with more difficulties in the case of 
HHV-7, and has not yet been achieved in the case of HHV-8. Human infection with HHV-6 and HHV-7 is ubiquitous, 
widespread and acquired early in life. HHV-8 epidemiology is still unclear, and there are two hypotheses: a restricted 
dissemination in the general population like herpes simplex virus type 2, or a widespread infection like all other human 
herpesviruses. The polymerase chain reaction is the common method for the detection of infection using specific primers 
and probes for HHV-6, HHV-7 and HHV-8 respectively. Serologic assays are only available for HHV-6 and HHV-7, with 
limitations being due, in particular, to possible cross-reactions with cytomegalovirus. HHV-6 is the causative agent of 
exanthem subitum (sixth disease). Its role as an opportunistic agent and immune dysfunction inducer is debated and 
currently under investigation. The pathogenic role of HHV-7 seems to be modest, with one case of exanthem subitum 
reported so far. HHV-8 is strongly associated with three diseases: Kaposi’s sarcoma, Castleman‘s disease and body- 
cavity-based lymphomas. The therapy against these novel viruses has to be considered in the future. 
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Three novel human herpesviruses have emerged in the 
past 10 years. Until 1986, five viruses of the Herpes- 
viridae fanlily were known to cause infections and 
induce diseases in humans: herpes simplex viruses 
1 and 2 (also called human herpesviruses 1 and 2), 
varicella-zoster virus (also called human herpesvirus 3), 
Epstein-Barr virus (also called human herpesvirus 
4) and human cytomegalovirus (also called human 
herpesvirus 5). These five viruses were classified into 
three subfamilies: herpes simplex viruses (HSV) and 
varicella-zoster virus (VZV) into the Alphaherpes- 
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virinae subfamily, human cytomegalovirus (CMV) into 
the Betaherpesvirinae, and Epstein-Barr virus (EBV) 
into the Gammaherpesvirinae. Like other herpes- 
viruses, these five ‘classical’ human herpesviruses 
chronically infect their hosts and are able to induce 
severe diseases, especially in imrnunocompromised 
persons. Infection is ubiquitous and widespread, 
concerning the majority of the general population, 
except for HSV2, which is quasi-exclusively trans- 
mitted by sexual contact and infects only a minority of 
the adult population. 
Human herpesvirus 6 (HHV-6), human herpes- 
virus 7 (HHV-7) and human herpesvirus 8 (HHV-8, 
also known as KSHV for Kaposi’s sarcoma-associated 
herpesvirus) were discovered in 1986, 1990 and 1994 
respectively. Their discovery illustrated the value of 
novel investigation procedures in human virology. 
These procedures were, in particular, the culture of 
lymphocytes in vitro thanks to the availability of 
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growth factors and the selective amplification of virus 
genomes using techniques derived fiom the polymerase 
chain reaction (PCR). The emergence of HHV-6, 
HHV-7 and HHV-8 has considerably modified the 
picture of human virus infections, although numerous 
questions remain unsolved. Primary characterization 
has indicated that the three novel herpesviruses share 
common properties. They all infect lymphocytes and 
can be detected in the peripheral blood of infected 
people, within the mononuclear cell fraction. How- 
ever, they appear to be clearly different from each other, 
and the amounts of data regarding each of them 
are very dissimilar. A lot of information has been 
progressively obtained about HHV-6, while the study 
of HHV-7 has been comparatively neglected. At 
present, numerous data are being collected about 
HHV-8 and tend to obscure the other domains of 
research on novel herpesviruses. However, major 
features concerning HHV-8 infection, such as its 
prevalence in the general population and its route of 
transmission, are still unknown. 
HUMAN HERPESVIRUS 6 (HHV-6) 
Virologic properties 
HHV-6 was first isolated from cultures of peripheral 
blood lymphocytes obtained from patients with various 
lymphoproliferative diseases [ 11. The objective of such 
cultures was the identification of novel human retro- 
viruses. A cytopathic effect was detected, consisting 
of enlarged refractile cells which were ultimately 
destroyed [2]. This cytopathc effect could be serially 
propagated but was not reminiscent of any retrovirus 
effect and was not associated with any reverse tran- 
scriptase activity. Infected cells were shown to contain 
viral particles exhibiting the morphology of herpes- 
viruses. No reactivity with either nucleic probes or 
antibodies specific for HSV1, HSV2, VZV, CMV and 
EBV was observed, which indicated that this human 
herpesvirus was a novel one. Initially named human 
B-lymphotropic virus (HBLV) because of an assumed 
preferential tropism for B-lymphocytes, this virus 
was later designated officially as HHV-6, when it 
became obvious that its main tropism was for 
T-lymphocytes [2,3]. 
The HHV-6 structure is very similar to that of 
other herpesviruses [3]. Enveloped virions, about 
200 nm in diameter, contain nucleocapsids which are 
100 nm in diameter and exhibit icosahedral symmetry. 
Capsids enclose a core in which the HHV-6 genome is 
located. This genome is composed of linear double- 
stranded DNA, approximately 167 kbp long, consisting 
of a 143-kbp unique region flanked by two identical 
directly repeated sequences. The complete nucleotide 
sequence of the HHV-6 genome has recently been 
obtained [4]. 
Two major facts have emerged from the genetic 
analysis of HHV-6. Although this virus is clearly 
distinct from the five ‘classical’ human herpesviruses, 
it is genetically related to CMV, as evidenced both by 
partial nucleotide sequence homologies and gene 
block colinearity [4-61. Recent data indicated that 
HHV-6 is also very closely related to HHV-7. 
This has led to the classification of HHV-6 into the 
Betaherpesvirinae subfamily. Some common pheno- 
typic properties, such as the sensitivity to antivirals in 
vitro [7] parallel the genetic relationship between 
HHV-6 and CMV. A second major property is the 
existence of two groups of viruses within the HHV-6 
species. These two groups can be unambiguously 
distinguished from one another by means of pheno- 
typic properties such as in vitro growth requirements, 
reactivity with panels of monoclonal antibodies, 
restriction endonuclease profiles and nucleotide 
sequencing [8,9]. Following a long debate on the 
hierarchical level of distinction between these two 
groups, regarding species, types and subtypes, they are 
now designated as the variants A and B of HHV-6 [lo]. 
The differences in disease association between variants 
A and B are less clear than the differences in virologic 
properties. Variant B is detected in peripheral blood 
much more frequently than variant A 1111, but with 
respect to pathogeny, the respective roles of the two 
variants are difficult to assess, especially because mixed 
infections seem to occur very often [12]. 
Although CD4 is not the cell receptor for HHV-6 
[13], the virus exhibits a marked tropism for CD4- 
positive T-lymphocytes [2,3]. It can also infect mono- 
cyte-macrophages and CD8-positive lymphocytes. 
Infection of CD8-positive cells with HHV-6 induces 
the expression of CD4 at the surface of cells, whlch, in 
turn, would make these cells susceptible to HIV 
infection [14]. HHV-6 infection has been obtained 
experimentally in continuous cell lines of various 
origins, including T-lymphocytes and megakaryocytic, 
glial and fibroblastic cells [3]. Generally speaking, 
adaptation to cell lines may be difficult or impossible in 
many cases. Primary peripheral or umbilical cord blood 
mononuclear cells remain the most convenient cells for 
isolation and serial propagation of most primary HHV- 
6 isolates. The virus is strongly cell associated and the 
yield of cell-free virus in culture supernatant is usually 
low. 
Epidemiology 
Prevalence studies using serologic assays have shown 
that HHV-6 infection is ubiquitous and widespread, 
A g u t  e t  a l :  N o v e l  h u m a n  h e r p e s v i r u s e s  1 6 1  
being present in most adults in all countries studied so 
far [3]. Differences of infection frequencies according 
to different authors reflect differences of sensitivity and 
specificity between distinct home-made serologic assays 
rather than high variations of virus dissemination 
according to geographic areas [15]. Antibody titers 
tend to decrease with age, which might lead to under- 
estimation of infection rates in adults. Primary infection 
occurs early in life. The rate of HHV-6-seropositivity 
and the titer of HHV-6-specific antibodies decrease 
from birth to 6 months old, corresponding to the loss 
of maternal antibodies. From 6 months up to 4 years 
old, the frequency of seropositivity continuously 
increases, and progressively reaches the level found in 
the adult population, from 60% up to more than 90% 
according to different authors [3,15]. 
Like other human herpesviruses, HHV-6 persists 
in the host after primary infection. This long-term 
infection is confirmed by the frequent detection of the 
virus in both the saliva and blood from healthy people 
at any age [11,16]. The precise rate of detection varies 
from one author to another, due to the different 
sensitivities of the assays used, but the reality of chronic 
HHV-6 infection is beyond doubt. Virus has been 
detected in salivary glands, lymph nodes and neurons. 
Several questions remain unanswered. It is not known 
whether the virus can stay in a real latent state for a long 
time or whether an active infection with low virus 
yields is always present. The preferential site of chronic 
infection is not precisely known, although blood 
mononuclear cells (and especially monocytes) and 
epithelial cells such as salivary gland cells are good 
candidates. It has been shown that a lot of HHV-6- 
infected people harbor the two variants of the virus, 
suggesting the possibility of co-infections or super- 
infections with two different viruses [12]. It is not 
known whether reinfections with the same variant can 
occur. The rate and the circumstances of infection 
reactivations in chronically infected subjects are not 
precisely known. Whether these reactivations associ- 
ated with viremia and, in some cases, increase of 
antibody titers are frequent or not, chronic HHV-6 
infection provides a large reservoir of virus capable of 
infecting susceptible subjects and maintaining the high 
rate of infection in the general population. 
Virus transmission is probably mediated by saliva in 
most cases, although a clear demonstration of that route 
is still missing. Breast milk does not seem to be 
implicated in transmission. Transmission though blood 
transfusion has not been reported [17]. Virus has been 
found in cervical secretion specimens, which might 
contribute to sexual and perinatal transmission. 
Intrauterine transmission of HHV-6 has been clearly 
demonstrated [MI. However, the frequency and the 
clinical manifestations of congenital HHV-6 infections 
are not known. 
Laboratory methods for diagnosis 
HHV-6 is isolated from peripheral blood mononuclear 
cells and diverse body fluids using lymphocyte culture 
techniques [3]. The most sensitive cells are primary 
phytohemagglutinin-stimulated lymphocytes of peri- 
pheral or umbilical cord blood obtained from healthy 
donors. Isolation in primary lymphocyte cultures is a 
reference method, but its sensitivity for the diagnosis of 
active HHV-6 infection appears to be limited. During 
the acute phase of exanthem subitum, isolation rates are 
above 90%, whereas isolation is much less efficient 
at the time of reactivations. The detection of virus 
multiplication in vitro was classically performed by 
microscopic observation of cytopathic effect [2,3]. The 
detection of virus antigens and genomes in cultured 
cells as well as in culture supernatant has been claimed 
to increase the sensitivity of isolation procedures, in 
parallel with improvements of culture conditions. 
However, no standardized highly sensitive method of 
isolation has been published so far. 
HHV-6 can be detected directly without any 
culture step by means of nucleic acid hybridization, 
in situ hybridization, PCR and in situ immunohisto- 
chemistry. PCR exhibits a high sensitivity, has been 
widely used, and has permitted us to define semi- 
quantitative methods using endpoint dilution [18, 191. 
This quantitation is of interest with respect to the 
distinction between ‘latent’ infection and acute in- 
fection or reactivation. Indeed, depending on the 
sensitivity of the PCR-based method, the rate of 
detection of HHV-6 DNA in blood cells from healthy 
people has been found to vary from 5% to more than 
90% [16]. In that sense, immunohistochemistry which 
detects virus antigen expression might be considered a 
more relevant approach than PCR for the diagnosis 
of acute infection. For both PCR and immunohisto- 
chemistry, special attention must be paid to the capacity 
of the method to detect either the two variants of 
HHV-6 or only a single one, according to study 
objectives. This requires a careful controlled evaluation 
of primers and probes for PCR, and monoclonal 
antibodies for immunohistochemistry. 
HHV-6 antibodies can be detected using distinct 
methods, and can be used either for the diagnosis of 
acute infection or the determination of infection 
prevalence in a group of subjects. Primary infection is 
associated with appearance of specific antibodies, 
including IgM at the beginning of seroconversion, 
and IgG thereafter. The presence of these specific 
antibodies is for life, provided that they remain at a 
detectable level in serum, and their titer does not appear 
162  Clinical  Microbio logy and Infect ion,  Vo lume 2 Number 3. December 1996 
to be correlated with the occurrence of diseases 
putatively related to HHV-6. Numerous assays have 
been described for HHV-6 serology, including 
immunofluorescence, enzyme-linked immunofluores- 
cence assay (EIA) and neutralization [3]. Neutrahzation 
assays are very specific but are time- consuming and not 
very sensitive. The most widely used test until now has 
been immunofluorescence, which is much less sensitive 
than EIA but probably more specific. Specificity is the 
key question of HHV-6 serology. Cross-reactions have 
been reported with CMV [20] as well as with HHV-7. 
This is a major drawback for both diagnosis and 
prevalence studies of HHV-6 infection. There is no 
validated variant-specific serologic assay. 
Clinical manifestations 
It is assumed that most primary HHV-6 infections are 
asymptomatic. The most common disease associated 
with primary infection is exanthem subitum, also called 
roseola infantum or sixth dsease [21]. Virus is isolated 
from blood at the acute phase of the disease; sero- 
conversion with appearance of specific IgM is observed 
during the convalescent phase. Primary infections are 
also associated with less typical manifestations such as 
febrile illness without rash, convulsions, hepatitis and 
mononucleosis [22-241. A few fatal cases associated 
with fulminant hepatitis, meningoencephalitis and 
disseminated infection have been reported [23,25]. Due 
to the high prevalence of infection early in life, primary 
infections of adults seem to be rare but with more 
severe clinical manifestations than for children. 
Clinical manifestations related to chronic infection 
and reactivations are far more complex [26]. The 
causative role of HHV-6 in opportunistic infections of 
immunocompromised subjects is suspected but not yet 
clearly established. Renal transplant recipients had 
significant rises of HHV-6 antibodies, and expression 
of HHV-6 antigens has been found in cases of kidney 
rejection [27]. In the case of bone marrow transplants, 
HHV-6 has been found in blood cells, lung and 
bone marrow samples, and virus detection has been 
associated with cases of CMV-negative pneumonitis 
and encephalitis [25,28,29]. In some cases of AIDS- 
associated retinitis, HHV-6 antigens and DNA have 
been detected in retina lesions [30] but the role of 
HHV-6 is unclear, given that CMV was also present in 
these lesions. Hence, the capacity of HHV-6 to induce 
disease in immunocompromised patients may be 
questioned. For these subjects, HHV-6 chronically 
infects mononuclear blood cells, which are susceptible 
to being recruited into inflammatory cell infiltrates, and 
this may act as a confounding factor. 
The possible interaction between HHV-6 and 
HIV-1 remains a matter of debate. Both viruses infect 
CD4 lymphocytes, and synergistic co-infection has 
been demonstrated in experimental infections in vitro. 
Simdarly, HHV-6-induced expression of CD4 in CD8- 
positive cells would provide additional susceptible cells 
for HIV infection [14]. In vivo, disseminated HHV-6 
infections were observed in patients who had died 
of AIDS [31]. However, many studies addressing 
either the titer of HHV-6 antibodies or the detection 
of HHV-6 DNA in body fluids during the course of 
HIV-1 infection did not support the hypothesis of 
a synergistic activation between the two viruses [32]. 
The possible role of HHV-6 in human malig- 
nancies has not been proven. Initially, the presence of 
HHV-6 DNA was demonstrated in tumoral tissue of 
non-Hodgkin’s lymphomas and Hodgkin’s disease. 
However, recent data from studies including samples 
from control lymphoid tissue did not demonstrate a 
significantly higher rate of detection in lymphomas 
than in non-neoplastic lymphoid tissue [12]. Despite 
initial claims, the involvement of HHV-6 in the pathol- 
ogy of chronic fatigue syndrome [33] or autoimmune 
diseases such as Sjogren syndrome has not been 
confirmed. The role of HHV-6 in multiple sclerosis 
needs further study [34]. Lastly, the capacity of HHV- 
6 to induce bone marrow suppression has been 
mentioned with respect to a limited number of cases. 
This must be compared with the capacity to inhibit 
bone marrow colony formation observed in vitro with 
HHV-6 infection [35]. 
Treatment 
Some antiviral agents are efficient against HHV-6 
infection in vitro [7]. The pattern of drug susceptibility 
mimicks that of CMV: HHV-6 is sensitive to ganci- 
clovir and foscarnet, and relatively resistant to acyclovir. 
No difference in sensitivity was observed between 
variants A and B. Antiviral chemotherapy has been used 
in a few cases of HHV-6 infection in bone marrow 
transplant recipients. However, no controlled study of 
antiviral efficacy in vivo has been performed and no 
precise indication for treatment has been defined. 
HUMAN HERPESVIRUS 7 (HHV-7) 
Virologic properties 
The isolation ofHHV-7 was first reported in 1990 [36]. 
The story started as the isolation of a novel strain of 
HHV-6 from a culture of purified CD4-positive 
peripheral blood T-lymphocytes obtained from a 
healthy individual. The cytopathic effects were 
very similar to those of HHV-6. Electronmicroscopic 
analyses confirmed the presence of a herpesvirus, but 
virus DNA did not hybridize with any of the HHV-6 
DNA probes tested, and the restriction enzyme pattern 
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differed widely from that observed for most HHV-6 
isolates. This virus was then considered to be a novel 
human herpesvirus, closely related to HHV-6, and 
designated as HHV-7. Subsequently, additional isolates 
of HHV-7 were obtained from saliva and peripheral 
blood mononuclear cells [37,38]. 
The HHV-7 structure was found to be very similar 
to that of HHV-6. HHV-7 DNA exhibited a close 
genetic relationship with the HHV-6 genome, with a 
partial homology of about 40% between the two 
viruses as depicted in preliminary studies [39]. The 
genomic architecture resembles that of HHV-6, with a 
long unique region of about 130 kb flanked by two 
terminal repeats and gene block organization similar to 
that of HHV-6 [40]. There is no doubt that HHV-7 is 
a member of the Betaherpesvirinae subfamily. 
HHV-7 grows in activated T-cells from peripheral 
blood or umbilical cord blood [41]. Target cells are 
quasi-exclusively CD4 positive, and it has been shown 
that CD4 is an essential component of the cell receptor 
for HHV-7 [42]. The fact that HIV-1 and HHV-7 share 
a common pathway of entry into cells might have 
major implications for the pathology and therapy of 
HIV infection. HHV-7 infection has been shown to 
have an inhibitory effect on HIV replication in vitro. 
Conversely, HIV-1 glycoprotein gp120 exhibited a 
dose-dependent inhibition of HHV-7 infection. The 
propagation of HHV-7 in continuous T-cell lines was 
found to be rather inefficient, while enrichment of 
mononuclear blood cells for CD4-positive T-cells 
resulted in an improved virus production after HHV-7 
infection. 
Epidemiology and diagnosis procedures 
The prevalence of HHV-7 infection in the adult popu- 
lation exceeds 90% [43]. Primary infection occurs early 
in life and it has been suggested that the time of this 
initial infection was slightly later for HHV-7 than for 
HHV-6. As with HHV-6, infection is lifelong. HHV- 
7 is found in saliva with high frequency, probably 
reflecting the fact that salivary glands comprise a major 
site of chronic HHV-7 infection [38]. It is therefore 
believed that s&va is a major route of transmission. 
HHV-7 can be isolated from saliva and mono- 
nuclear blood cells, but this isolation is rather inefficient 
when compared with the high frequency of HHV-7 
DNA detection, particularly in saliva samples. Culture 
conditions remain to be improved to increase the rate 
of isolation. In this context, PCR detection of HHV- 
7 DNA is the most convenient approach for the 
diagnosis of HHV-7 infection in body fluids. So far, no 
distinction between ‘latent’ and active infection based 
on PCR results has been published. Several monoclonal 
antibodies to HHV-7 have been described and may 
contribute to the direct detection of HHV-7-antigen- 
expressing cells. Diverse home-made serologic assays 
starting from HHV-7-infected cells as the source of 
antigen and using different read-out techniques such 
as immunofluorescence, immunoblot or ELISA have 
been published. The main question is the possibility of 
cross-reactions with either HHV-6 or CMV antibodies. 
Clinical manifestations and treatment 
So far, no human disease has been clearly linked to 
HHV-7 infection, except one case of an exanthem 
subitum-like syndrome associated with primary infec- 
tion [44]. As with HHV-6, the role of HHV-7 as a 
cofactor in AIDS as well as an opportunistic agent in 
infections of immunocompromised people has been 
discussed but not proven. 
In vitro sensitivity of HHV-7 to antiherpetic drugs 
has not been extensively studied. Preliminary data 
indicate that HHV-7 infection is inhibited by foscarnet 
and ganciclovir but not by acyclovir. 
HUMAN HERPESVIRUS 8 (HHV-8) 
Virologic properties 
The causative role of an infectious agent for Kaposi’s 
sarcoma (KS) had been suspected for a long time on the 
basis of epidemiologic data [45]. The hypothesis of 
a viral etiology has been mentioned previously [46]. 
The recent discovery of HHV-8 (also called Kaposi’s 
sarcoma-associated herpesvirus) was founded on a pure 
molecular biology approach, in contrast with the initial 
isolation of HHV-6 and HHV-7. Starting from two 
distinct samples from the same subject, one from a KS 
lesion and the other from adjacent unaffected tissue, 
Chang et al. applied representational difference analysis 
and identified two DNA fragments, 330 and 631 bp 
long respectively [47]. These fragments were assumed 
to correspond to the genome of the putative causative 
agent of KS. These two fragments exhibited homology 
with the genomic DNA of two viruses, EBV and 
herpesvirus saimiri (HVS), both members of the 
Gammaherpesvirinae subfamily. One fragment (330 bp 
long) encoded a putative protein homologous to 
capsid proteins of EBV and HSV. Similarly, the second 
fragment (631 bp long) encoded a putative protein 
homologous to tegument proteins of EBV and HVS. 
These homologies were confirmed on larger 6-agments 
cloned from genomic DNA banks [48,49] and led to 
the conclusion that the DNA fragments obtained were 
part of the genome of a novel herpesvirus. 
At present, little is known about the structure 
of HHV-8 DNA. Preliminary data indicated a size of 
270 kbp [50], but more recent analyses tend to 
demonstrate that this size is indeed close to 140 kb. 
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Primary sequence analyses of HHV-8 DNA amplified 
from distinct subjects showed a few changes which 
indicated some degree of genetic polymorphism 
[5 1,521. 
In vitro propagation of HHV-8 is very difficult. 
Following numerous unsuccessful attempts, the virus 
was ultimately obtained under a cell-fiee form after 
chemical induction of a chronically infected cell line 
[53,54]. This virus-producing cell line, like other 
chronically infected ones, was derived from a body- 
cavity-based lymphoma (BCBL). Most of these cell 
lines also contain EBV DNA sequences, which makes 
specific analysis of HHV-8 sequences difficult [55]. In 
vivo target cells for HHV-8 infection include CD19- 
positive B lymphocytes [56]. 
Epidemiology and diagnosis procedures 
The prevalence of HHV-8 infection in the general 
population is not yet known, due to the lack of an 
accessible serologic assay. Two hypotheses must be 
considered: either HHV-8 infection is present in a small 
percentage of population, like HSV-2, or HHV-8 
infection is widespread and ignored in most cases, as for 
other human herpesviruses. Both hypotheses are 
supported by results which, taken together, look 
conflicting. On the one hand, HHV-8 DNA has not 
been found frequently, if at all, in the mononuclear 
blood cells from healthy subjects, and preliminary 
serologic assays indicate that specific HHV-8 antibodies 
are detected only in patients with KS or at risk of 
developing KS [48]. On the other hand, HHV-8 DNA 
has been found in sperm [57] and lymph nodes of 
numerous people who were healthy or not at risk of 
KS. However, it is possible that the prevalence of HHV- 
8 infection differs according to ethnic group or 
geographic area. 
The route of virus transmission is unknown. 
Because the putative infectious agent responsible for KS 
was suspected to be transmitted by sexual contact, it has 
been hypothesized that this would be the case for 
HHV-8, but no definite proof has yet been provided. 
The virus is not frequently found in saliva. Some 
authors have reported a high detection frequency in 
sperm &om both homosexual men (91% of samples) 
and healthy donors (23% of samples), but these results 
[57] are controversial. In most reports, the presence of 
HHV-8 DNA sequences in blood cells is restricted to 
patients with HHV-8-associated disease (see below). 
Since the initial description of HHV-8, detection 
of HHV-8 infection has been done by means of PCR 
[47,51,52]. This has permitted the demonstration of 
the presence of the virus in tissue lesions as well as in 
normal human tissues. Isolation and serial propagation 
of the virus in vitro has not been clearly achieved so far 
using conventional lymphocyte cultures. Serologic 
assays are currently under development. An immuno- 
fluorescence assay using a chronically infected cell line 
as an antigen has been described and provided evidence 
that KS patients have higher HHV-8 antibody titers 
than controls [48]. However, due to the concomitant 
presence of EBV in the cell line, the preliminary 
adsorption of serum EBV antibodies on EBV-infected 
cell lines is required. Preliminary results have been 
reported using immunoblot assays. The prevalence of 
HHV-8 infection with one of these immunoblot assays 
is 77.5% among HIV-positive subjects with KS, 17.5% 
among control HIV-positive subjects, and 0% among 
healthy blood donors (P. Moore, personal communica- 
tion), some very interesting data whch deserve hrther 
investigation. 
Clinical manifestations and therapy 
HHV-8 infection has been associated with all forms of 
KS: AIDS-associated KS, classical or Mediterranean 
KS, endemic or African KS, and post-transplant KS 
[58-651. Virus is detected in nearly 100% of tissue 
lesions. Virus is also present in adjacent normal skin 
(591 and in peripheral blood mononuclear cells from 
KS patients [52,58], but with a lower fiequency and/or 
level than in KS lesions. Prior to the occurrence ofKS, 
the detection of HHV-8 in blood cells is predictive of 
the disease. In situ PCR has shown that HHV-8 DNA 
was present in the nucleus of endothelial and spindle 
cells within the tumor [66,67]. Surprisingly, the virus 
is not detected any longer within continuous cell 
cultures derived from KS lesions [61]. 
HHV-8 is also detected in BCBL [68-701 and virus 
load is very high, ranging &om 40 up to 80 copies of 
virus genome per cell. This high virus load permitted 
the detection of HHV-8 DNA not only by means of 
PCR but also by means of Southern hybridnation. 
These findings are in contrast with those obtained 
for other forms of non-Hodgkin’s lymphomas: both 
detection rate and virus load are much lower than for 
BCBL [71] (unpublished results). 
Castleman’s disease, a lymphoid tissue disease 
characterized by polyclonal lymphoid proliferation 
and vascular hyperplasia, is associated with HHV-8 
infection [72-741 in both HIV-positive and HIV- 
negative individuals. The virus is detected in lymph 
node biopsies, and mononuclear blood cells. 
It is not yet possible to have a clear picture of the 
role of HHV-8 in the three diseases mentioned above. 
HHV-8 belongs to the Gammaherpesvirinae subfandy, 
some members of which, such as EBV and HVS, are 
involved in oncogenesis processes. It is tempting to 
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conclude that HHV-8, a B-lymphotropic herpesvirus, 
is responsible for lymphoid tissue proliferation and KS. 
However, a simple role of passenger virus for HHV-8, 
the multiplication of which would be promoted in the 
context oflymphoid tissue diseases, cannot be ruled out. 
The characterization of the pathogenic role of 
HHV-8 deserves further study and will probably require 
numerous investigations. A possible approach is the 
study of antiherpetic drug effects on HHV-8-associated 
diseases. The study of the effects of foscarnet on KS has 
provided conflicting results [75-771. However, the 
report of KS tumor remission following foscarnet 
therapy must be considered. 
FUTURE PERSPECTIVES FOR NOVEL 
HERPESVIRUSES 
The recent description of three novel human herpes- 
viruses undoubtly opens new avenues for medical 
virology. It is surprising to observe that HHV-6 and 
HHV-7, two viruses which, taken together, infect 100% 
of the adult population, were still unknown 10 years 
ago. The question of the prevalence of HHV-8 is being 
investigated and will focus medical attention in the next 
months. The most recent data strongly suggest that 
HHV-8 is not ubiquitous, afleast in the populations of 
Western countries [78,79]. These viruses are in search 
of their pathology and, again, most research efforts in 
the near future will probably concentrate on HHV-8, 
because of the seriousness of potentially associated 
diseases. An additional reason for developing research on 
novel herpesviruses concerns efficient antiviral therapy. 
A wide set of antiherpetic drugs is now available in 
clinical settings, and some others are in development 
with good prospects of efficient medical use. It would 
be a pity to m i s s  this opportunity of therapy if the 
causative role of novel herpesviruses in serious diseases 
is clearly demonstrated. 
Lastly, lymphotropism is a common property 
shared by novel herpesviruses. The possibility of inter- 
actions between these viruses and other viruses 
infecting lymphoid tissue, such as HIV, raises the hope 
of a better understanding of immune dysfunctions. This 
pathway of investigation cannot be neglected, since, if 
necessary, specific therapy appears to be a reasonable 
goal. In addition, the use of viral vectors derived from 
these novel herpesviruses and targeted to special 
populations of lymphocytes could constitute the basis 
of attractive projects. 
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